Why has this not been disclosed to the market and the...

Why has this not been disclosed to the market and the ramifications put to the shareholders?

Epi-LASIK: 6-month results of an advanced surface ablation procedure
Pallikaris I, Katsanevaki F, Kymionis G Heraklion,
Kreta, GR


Purpose: To evaluate the efficacy and safety of Epi-LASIK for the treatment of low myopia and myopic astigmatism.
Methods: 162 eyes of 108 patients were treated with Epi-LASIK for low myopia and myopic astigmatism. Epithelial mechanical separation was performed with the use of Centurion Epikeratome® (Norwood Abbey, Australia). Preoperative spherical equivalent ranged from -1.75 D to -7.75 D and best-spectacle corrected (BSCVA) from 0.50 to -0.10 log MAR.
Results: Epithelial separation was successfully performed in all 162 eyes. The epithelial healing was completed within 4.64 ± 0.82 days (range 3 to 6 days). The mean log MAR UCVA on the day of reepithelization was 0.25 ± 0.13 (range 0.40 to 0.0 0). The spherical equivalent was -0.30 D ± 0.61 D (N = 142) at one-month postoperative interval, -0.19 ± 0.44 at three months (N = 111), and -0.21 ± 0.37 at six months postoperatively (N = 79). 52 eyes (47%) and 46 eyes (58%) gained one to two lines of BSCVA at three and six months respectively. 98% of the Epi-LASIK treated eyes had clear corneas or trace haze by the sixth postoperative month.
Conclusion: Preliminary clinical results suggest that EpiLASIK is a safe and effective modality for the treatment of low myopia.